News Search Results
Jun 29, 2026, 07:00 ET Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases
and WESTFIELD, N.J., June 29, 2026 /PRNewswire/ -- Talawar Tx Inc. ("Talawar" or "Talawar Therapeutics"), a biotechnology company developing potentially best-in-class bispecific antibodies that pair independent immunology & inflammatory (I&I) disease drivers
More news about: Talawar Therapeutics
Jun 29, 2026, 03:58 ET Positive interim analysis advances Avecho Phase III insomnia program
MELBOURNE, Australia, June 29, 2026 /PRNewswire/ -- Avecho Biotechnology Limited (ASX: AVE) ("Avecho" or "the Company") has announced it will continue with recruitment for its world-first Phase III insomnia program following
More news about: Avecho Biotechnology Limited
Jun 27, 2026, 17:53 ET "UK-India Free Trade Agreement will be India's most comprehensive agreement so far": Piyush Goyal at UK-India Week 2026
building an island. It's about building bridges that make Britain stronger and give us greater leverage."The Forum also examined the future of biotechnology and life sciences, with Kiran Mazumdar-Shaw, Chairperson, Biocon Ltd, highlighting the transformational role of AI."Biotech is a huge
More news about: India Global Forum (IGF)
Jun 27, 2026, 10:07 ET Qianhai Ehub Brings Greater Bay Area Innovation to VivaTech Paris 2026
Paris, including Vispek, GEE•D, InnAIO, SkylandX, GastroEase Biotech and i2Cool, representing sectors such as artificial intelligence, biotechnology, green technology and smart hardware.Throughout the exhibition, the delegation presented their solutions to global investors, industry leaders
More news about: Ehub
Jun 26, 2026, 20:11 ET Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing
June 26, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across
More news about: Decoy Therapeutics, Inc
Jun 26, 2026, 16:30 ET Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
of the stock option and RSU agreement covering the grant.About Nektar TherapeuticsNektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
Jun 26, 2026, 13:10 ET Piyush Goyal and UK-India FTA Negotiation Teams Honoured at 10th Anniversary of IGF UK-India Awards
individuals and institutions that have helped strengthen the UK-India partnership and advance it into a new phase of economic cooperation.Biotechnology pioneer and Chairperson of Biocon Group Kiran Mazumdar-Shaw was presented with the Lifetime Contribution to UK-India Relations award
More news about: India Global Forum (IGF)
Jun 26, 2026, 10:30 ET Epigenetics Market worth $3.92 billion by 2031 | MarketsandMarkets™
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=896The epigenetics market is expanding as pharmaceutical and biotechnology companies, clinical laboratories, CROs, and academic research institutes increasingly adopt epigenomic technologies to support drug discovery, oncology
More news about: MarketsandMarkets
Jun 26, 2026, 09:42 ET Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split
LEXINGTON, Mass., June 26, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that
More news about: Curis, Inc.
Jun 26, 2026, 09:31 ET Lupin Receives Tentative Approval from U.S. FDA for Enzalutamide Tablets
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Pharmaceuticals, Inc.
Jun 26, 2026, 09:10 ET Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its two clinical-stage immunotherapy programs were presented at
More news about: Anixa Biosciences, Inc.
Jun 26, 2026, 09:01 ET Nippon Shinyaku and Elixirgen Therapeutics Enter Option Agreement for Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy
nippon-shinyaku.co.jp/english.About Elixirgen Therapeutics, Inc.Elixirgen is a clinical stage biotechnology company focused on the treatment of rare and aging-associated diseases using its cutting-edge technologies. For more information, visit
More news about: NS Pharma, Inc.
Jun 26, 2026, 09:00 ET NextRise 2026, Seoul Successfully Wraps Up as Asia's Leading Startup Fair Co-hosted by KITA and KDB
conference program shared global trends and practical insights through more than 60 expert sessions on future strategic industries, including AI, Biotechnology, Creative Industry, and defence, as well as strategies for startups seeking overseas expansion. Major sessions included OpenAI Head of Startups
More news about: Korea International Trade Association
Jun 26, 2026, 08:30 ET FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
June 26, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts
More news about: FibroBiologics, Inc.
Jun 26, 2026, 07:16 ET Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Jun 26, 2026, 04:23 ET Lilly launches "The Memory Radio Station" across Europe, inviting the public to visually reconstruct fading memories through GenAI
pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Jun 26, 2026, 04:00 ET NextRise 2026, Seoul Successfully Wraps Up as Asia's Leading Startup Fair Co-hosted by KITA and KDB
conference program shared global trends and practical insights through more than 60 expert sessions on future strategic industries, including AI, Biotechnology, Creative Industry, and defence, as well as strategies for startups seeking overseas expansion. Major sessions included OpenAI Head of Startups
More news about: Korea International Trade Association
Jun 25, 2026, 17:29 ET Pendulum Therapeutics Appoints Madison Reed Founder and CEO Amy Errett to Board of Directors
Pendulum Therapeutics, the leading biotechnology company pioneering microbiome science to transform human health, today announced the appointment of Amy Errett, Founder and CEO of Madison Reed,
More news about: Pendulum Therapeutics
Jun 25, 2026, 17:19 ET Marquis Who's Who Honors Shawn Patrick O'Brien for Expertise in Pharmaceuticals and Biotechnology
Shawn Patrick O'Brien for his expertise in pharmaceuticals and biotechnology. Mr. O'Brien is a seasoned professional in the pharmaceutical industry with over four decades of experience.
More news about: Marquis Who's Who
Jun 25, 2026, 15:25 ET Report: America's Health Care Workforce Shortage Threatens Patient Access and Economic Competitiveness
educators to introduce students and early-career nurses to apheresis, building awareness of a critical and specialized field enabling the future of biotechnology.Build the health care workforce across the full career journey, as demonstrated by the focus of Covista Open Doors, a multiyear
More news about: The Conference Board
Jun 25, 2026, 13:24 ET Precision Fermentation Ingredients Market to Reach USD 136.6 Billion by 2036 as Biotechnology Innovation Accelerates Sustainable Ingredient Production, FMI
continue to demonstrate strong adoption due to advanced biotechnology ecosystems, food innovation investments, and increasing demand for sustainable ingredients.Asia Pacific is emerging as a high-growth region due to expanding biotechnology infrastructure, government support, and rising food security
More news about: Future Market Insights
Jun 25, 2026, 10:49 ET WORLD BUSINESS CHICAGO ANNOUNCES THE RETURN OF CHICAGO VENTURE SUMMIT WITH A FOCUS ON HEALTH
life sciences and biotechnology investment, the BioBuilders Summit echoes the Midwest's industrial spirit, highlighting companies and platforms dedicated to translating breakthroughs into market-ready products and building the infrastructure needed for the next era of biotechnology. You can learn more
More news about: World Business Chicago
Jun 25, 2026, 10:30 ET Cell Culture Market worth $58.42 billion by 2031 | MarketsandMarkets™
end user, the pharmaceutical & biotechnology companies segment is estimated to register the highest growth in the cell culture market during the forecast period.Based on end user, the cell culture market is segmented into pharmaceutical & biotechnology companies, hospitals & diagnostic
More news about: MarketsandMarkets
Jun 25, 2026, 09:20 ET NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced positive biomarker findings from its Phase 2, randomized,
More news about: NeuroSense
Jun 25, 2026, 08:47 ET LyGenesis Receives Award from Breakthrough T1D® to Fund a Research Project to Induce Immune Tolerance to Pancreatic Islet Transplantation
LyGenesis, Inc., a clinical-stage biotechnology company developing cell therapies for organ regeneration, today announced a research award from Breakthrough T1D, the leading global type 1 diabetes
More news about: LyGenesis